[Special Stock] FutureChem Rises 12% on Phase 2 Clinical Trial Results of Prostate Cancer Treatment

FutureChem is showing strong performance in the early trading session. The stock price surged following the announcement of clinical results showing that the company's radiopharmaceutical candidate FC705 demonstrated the highest tumor reduction rate in patients with advanced prostate cancer.

As of 9:09 AM on the 9th, FutureChem is trading at 22,750 KRW, up 11.79% (2,400 KRW) from the previous day.

Earlier, FutureChem announced that it had received the final Clinical Study Report (CSR) for the Phase 2 clinical trial of FC705 for prostate cancer. The purpose of this clinical trial was to evaluate the safety and efficacy of administering 100 mCi of FC705 up to six times at 8-week intervals to 20 patients with metastatic castration-resistant prostate cancer (mCRPC).

Although the average dose per administration was 100 mCi, which is half the dose compared to competing drugs, up to 73.3% of patients showed a reduction in prostate-specific antigen (PSA)?a blood biomarker used to evaluate prostate cancer treatment?by more than half (based on Best PSA-PR criteria). The objective response rate (ORR) and disease control rate (DCR), the most widely used efficacy indicators in Phase 2 oncology trials, were also high at 60% and 93.3%, respectively.

Minyong Eom, a researcher at Shinhan Investment Corp., commented, "FC705 announced an impressive 60% objective response rate with only about one-third the dose compared to Novartis's Pluvicto. This represents the highest efficacy among global competitors and surpasses the efficacy and safety results of Novartis's Pluvicto Phase 2/3 trials."